Table 1. Clinical characteristics of subjects enrolled in this study.
| PEG-IFNα/RBV | PEG-IFNα/RBV+VD3 | PEG-IFNα/RBV+VD3 | ||
| (n = 42) | (n = 42) | With Pre-VD3 | Without Pre-VD3 | |
| (n = 18) | (n = 24) | |||
| Gender(M/F) | 19/23 | 15/27 | 6/12 | 9/15 |
| Age | 58.3(35–72) | 59.1(29–71) | 58.6(29–71) | 58.5(43–71) |
| Body Weight | 58.4 | 58.1(41.2–81) | 56.4(41.2–81) | 59.4(43–78) |
| History of IFN(+/−) | 13/29 | 13/29 | 7/11 | 6/18 |
| IL-28B(TT/TG,GG) | 29/13 | 29/13 | 10/8 | 19/5 |
| Sampling Point (week) | 0W | All 0W | −4W | 0W |
| HCV-RNA | 6.3(5.1–7.2) | 6.3(5.2–7.4) | 6.3(5.2–7.1) | 6.4(5.3–7.4) |
| ALT | 68.5 (15–234) | 66.4(16–242) | 47.9(22–108) | 78(16–242) |
| AST | 55.2(16–161) | 58.1(21–251) | 45.3(22–112) | 66.1(21–251) |
| WBC | 5045(3050–7800) | 5165(2400–9300) | 5055(3100–9300) | 5530(2400–8130) |
| RBC | 441.3(355–522) | 441.5(375–567) | 450(375–567) | 446(383–515) |
| PLT | 16.6(9.4–29.4) | 16.7(9.3–27.6) | 16.6(9.3–27.6) | 16.7(9.3–23.9) |
| Nue | 2845(1750–5020) | 2911(1190–7160) | 2792(1190–7160) | 3476(1533–5070) |
| Hb | 13.8(11.8–15.9) | 13.6(12–16.3) | 13.7(12–15.2) | 14.1(12.6–16.3) |
| Serum Ca | 9.3(8.5–9.8) | 9.2(8.6–10.1) | 9.4(8.9–10.1) | 9.2(8.6–10) |
| Insulin | 9.4(6.8–20.2) | 9.5(1.6–25.5) | 9(4.76–20.8) | 9.6(1.6–25.5) |
| T-cho | 170.6(118–214) | 172.4(116–227) | 168.2(116–226) | 173.7(119–227) |
| TG | 108.5(55.6–210) | 106.4(37–427) | 118.9(37–259) | 103.2(51–427) |
HCV-RNA(log copies/ml), ALT(U/l), AST(U/l), WBC(counts/µl), RBC(x103counts/µl), PLT(x104counts/µl), Neut(counts/µl), Hb (g/dl), Serum Ca (mg/dl), Insulin (µU/ml), T-cho (mg/dl), TG (mg/dl).